Next generation riluzole prodrugs

WO2025191529A1PCT designated stage Publication Date: 2025-09-18BIOHAVEN THERAPEUTICS LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2025/052713
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-14
Filing Date
2025-03-14
Publication Date
2025-09-18

Smart Images

  • Figure IMGF000007_0001
    Figure IMGF000007_0001
  • Figure IMGF000007_0002
    Figure IMGF000007_0002
  • Figure IMGF000007_0003
    Figure IMGF000007_0003
Patent Text Reader

Abstract

A pharmaceutical composition includes about 100 mg to about 280 mg of troriluzole, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of the salt, wherein the pharmaceutical composition is in a once-a-day oral dosage form, which provides an AUC0-inf for riluzole of about 80% to about 125% of about 791 h•ng / mL to about 2330 h•ng / mL. A method of treating a disease or a condition in a patient in need thereof includes administering to the patient once daily the pharmaceutical composition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]-- - , , .. . ,,. . - --, ' . , . ,. - ,.,..,, , -, .- , - ..,.., . , . ,. . , . , , , , - ., ,. -- - , , -- , • , , • .-n, , ,, ,-- • , • .-n. . , , - . - . - . . . . . . . . -- - ,. - ,- ,max. - - . - . . , , . , . . , "" "" "" . , " "” """ . "." ,.., , .., . . "" -- - , , . "" , ,, , , , ,. , " ". , ,. ., ,, ,, ,, , , , , , , , , , , , , , , , , , , , , , ,- , , - , , , -2n- ,,., . ,, ,..,. . . -, ., ,. , "," " " ,..,..,, . ,-, , , .. " " " " ," "," -- . "- , , , , , . , . -- - " " " " , , , , , " ". , . , " "" ,", , . "" . . , .-n.ss. "" , -,. "” - , ., "max" , , , . .max.max,ss- , , “max” ,max"ma,x" . max, , , ".-” -. . -- - - . - -- . . . . ,, , . , . , , . . , .., . , , ..,, , , , , . , , --. • •-n• .-n • . , -- - -n -n• • • . • . , , .,-n, ., • • . ,, ,-n,, .., • • . , “ ”, ., ., -n“ ” . , , -, -.n, ,- - .-n, -n., , -max, - ,max. . - ,., ,, , . ,-n. -- - .,, . ,-n -n. .-n. , , ,, ,, , ,, , , , , . , , , ,, ,, , , , , , , , , ,, ., , . ' , , , , , , ,. . , .. , , “ ” . , . ,. “'.” , ,- , , , , , , , ,, . . -- - , , , , , . , , , , . , . . , ..,., , , , , . ., , , ,, , , , ,,,, ,, , ,,, ,, , , , , ,, ,, , , , , , , , , ,, , , , , , .. , , , , , , , , , ., , , - . . , . , , , , , ,. , , -- - , , , ,,,, , , - . , , , , , ,.., .,.., , , .., .. . , , ,, ., . . , , , , , , , - , , . , , . , , , , , , . , . , ,, ,,, , , , , , ,, ..,, , . , ' , ,, ,,, . , -- - , .., . , ... , . . . , - . , . , , , , ,,-, ,, ,, , , , , , , - , , , , , , ,- . , , ' , ,, , ' ,, , , , , ' ,' ,, , . , , , , , ,, , , , ,, , , , , , , , , , , , , , , ,, , -- - ,, ,, , , , , . ,, , ,.., . , , , . , , , ,.., . - , - - - . , - , , , - - -- - - .- . ,..,-..- .,, ,,, .,..., -,-., --- ,- - . -. " ", , - , -,,,-, - -- .,.-., -, - ,, ....,,. , -,, " ", -- - .,, ,,. -. , ,... " " -, , ,, - ,,,. , ,.... , - , , , ,, ,., , .,.. ,- , - - . ---, , , . .-. . ... , . , . , , , , . . . , ,. , , , .,, . , , . . - . -- - . , , . , -, -, -, . - , - . . - - = . . - - = . . - - = . .. , -- - . . . . , . x , , - ma.-nc •-nmax.. . a . .c•-n. . =conmaxencenerva= coec.en o vara . . a.o weorsee- mnourmaze0-infanmaxorreamenon. mroruzoeo a m ruzoeose,0-infan c..maxacuaeoeme usrnce *ea wsa as s c . cuoaarcrreuecsa moeena anacscc ooonrr onn-raonsoer.moermuaa:a e axccornoeormua: eexsua* *. -n-, ,, , ,max ma. max. . .x~ . -- - . - -. . . - .-n max•-n. . .a. =conmaxencener . . . . . a.acuae usnveaas su=ares c moeeancse onn on varaon. ..eomerc cacuae a -ransormeaa accornoeormua: ex * . ccornoeormua: ex esua* * - . ,mmaxax. - . , -. - , , – ,. . -- - . , . , ,. . , ,.. ..., - . - - - .. ,. , . . , , . .. -- - - , . ,. - ,-max, . , - = ., . . , , - - - - . ,-1.. - - .. ,1-.. ,, -a..... ,, -. -.... , .... .... -- - a o.rr ..oarcuo mzn moa e ooe es .s wme ecxae o ere ososr seo -r e. o auszo rrooe ur azco oucoez rousnuez e co xoerro a e mrsom seeenc m ausosanr rrao wo uzen, oreareanso a ssaeerrm memne ooceeer ccunuom aaror ws wee eeose - ... . .. ..... . .. . . . . . ... .... .. .... . . .- . , ~. . , . ~. , ~.- , - ., ~ -,. . , . . - - - - -- - , .- -24,max,max. - , =. max max,ss m. . .-a2x4~ - . , , , - , . . . ,, , , -- • , , • .-n. • , • .-n.-n, ..- , , --n --nn, -- - . . - , , , . . n-n, -n. ., - . -n . , , , . , ., , , , , . , ., . , . , . . ., . . , , . , , , -n-- • , • . -- - . • ,-n. •, . -n. . - , , , . , . --n -n n.-n. , ,.. , , ., . , , , , . , ,, , . , . , , , , , , . , , , , . -- - ,. , , , , , , .

Claims

-- - . , , , -- , • , , • .-n. • , • .-n.-n, . , , , . - , , --n --nn, , ., , . - , , , , . , ,-- - . - ,n n. ,-n --n.. . , , , ., . , , , . , , . , . . . , . . , . . , ., -, , , -n- • , • .-- -. • , • .-n.-n, , . , ,. , , , - , , . ,.-n, -n -n-n. ,.. . , , , .,. , , , ., ,-- -. ,, .

Citation Information

Patent Citations

  • Human CTLA-4 antibodies

    US6984720B1

  • Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

    US7943743B2

  • Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics

    US8008449B2

  • Antibodies to human programmed death receptor PD-1

    US8354509B2

  • Antibodies to human programmed death receptor PD-1

    US8900587B2